Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib

British Journal of Haematology

Volumn 141, Issue 4, 2008, Pages 494-503

  Nerini Molteni, Silvia ^a   Ferrarini, Marina ^a   Cozza, Sara ^a   Caligaris Cappio, Federico ^a,b   Sitia, Roberto ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Glutathione; Multiple myeloma; Nrf2; Proteasome inhibitors; Redox homeostasis

Indexed keywords

BORTEZOMIB; BUTHIONINE SULFOXIMINE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HEME OXYGENASE 1; TRANSCRIPTION FACTOR NRF2;

ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG ACTIVITY; HOMEOSTASIS; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACETYLCYSTEINE; ACTIVATING TRANSCRIPTION FACTOR 4; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BORONIC ACIDS; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GLUTATHIONE; HOMEOSTASIS; HUMANS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; OXIDATION-REDUCTION; PROTEASE INHIBITORS; PYRAZINES; TRANSCRIPTION FACTOR CHOP; TUMOR CELLS, CULTURED;

EID: 42249109833     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07066.x     Document Type: Article

References (46)

1. Adams, J., Behnke, M., Chen, S., Cruickshank, A.A., Dick, L.R., Grenier, L., Klunder, J.M., Ma, Y.T., Plamondon, L. Stein, R.L. (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorganic & Medicinal Chemistry Letters, 8, 333 338.
2. van Anken, E., Romijn, E.P., Maggioni, C., Mezghrani, A., Sitia, R., Braakman, I. Heck, A.J. (2003) Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion. Immunity, 18, 243 253.
3. Bailey, H.H., Ripple, G., Tutsch, K.D., Arzoomanian, R.Z., Alberti, D., Feierabend, C., Mahvi, D., Schink, J., Pomplun, M., Mulcahy, R.T. Wilding, G. (1997) Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. Journal of the National Cancer Institute, 89, 1789 1796.
4. Caligaris-Cappio, F., Bergui, L., Gregoretti, M.G., Gaidano, G., Gaboli, M., Schena, M., Zallone, A.Z. Marchisio, P.C. (1991) 'Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood, 77, 2688 2693.
5. Cenci, S., Mezghrani, A., Cascio, P., Bianchi, G., Cerruti, F., Fra, A., Lelouard, H., Masciarelli, S., Mattioli, L., Oliva, L., Orsi, A., Pasqualetto, E., Pierre, P., Ruffato, E., Tagliavacca, L. Sitia, R. (2006) Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO Journal, 25, 1104 1113.
6. Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T.A. Anderson, K.C. (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood, 87, 1104 1112.
7. Chauhan, D., Li, G., Sattler, M., Podar, K., Mitsiades, C., Mitsiades, N., Munshi, N., Hideshima, T. Anderson, K.C. (2003) Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene, 22, 6296 6300.
8. Chauhan, D., Li, G., Podar, K., Hideshima, T., Shringarpure, R., Catley, L., Mitsiades, C., Munshi, N., Tai, Y.T., Suh, N., Gribble, G.W., Honda, T., Schlossman, R., Richardson, P., Sporn, M.B. Anderson, K.C. (2004) The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood, 103, 3158 3166.
9. Chen, Q., Chai, Y.C., Mazumder, S., Jiang, C., Macklis, R.M., Chisolm, G.M. Almasan, A. (2003) The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation, and mitochondrial dysfunction. Cell Death and Differentiation, 10, 323 334.
10. Cullinan, S.B. Diehl, J.A. (2006) Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. International Journal of Biochemistry and Cell Biology, 38, 317 332.
11. Cullinan, S.B., Zhang, D., Hannink, M., Arvisais, E., Kaufman, R.J. Diehl, J.A. (2003) Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Molecular and Cellular Biology, 23, 7198 7209.
12. Emanuele, S., Calvaruso, G., Lauricella, M., Giuliano, M., Bellavia, G., D'Anneo, A., Vento, R. Tesoriere, G. (2002) Apoptosis induced in hepatoblastoma HepG2 cells by the proteasome inhibitor MG132 is associated with hydrogen peroxide production, expression of Bcl-XS and activation of caspase-3. International Journal of Oncolgy, 21, 857 865.
13. Fojo, T. Bates, S. (2003) Strategies for reversing drug resistance. Oncogene, 22, 7512 7523.
14. Fribley, A., Zeng, Q. Wang, C.Y. (2004) Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Molecular and Cellular Biology, 24, 9695 9704.
15. Ghia, P., Granziero, L., Chilosi, M. Caligaris-Cappio, F. (2002) Chronic B cell malignancies and bone marrow microenvironment. Seminars in Cancer Biology, 12, 149 155.
16. Girlanda, S., Fortis, C., Belloni, D., Ferrero, E., Ticozzi, P., Sciorati, C., Tresoldi, M., Vicari, A., Spies, T., Groh, V., Caligaris-Cappio, F. Ferrarini, M. (2005) MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes. Cancer Research, 65, 7502 7508.
17. Glickman, M.H. Ciechanover, A. (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiological Reviews, 82, 373 428.
18. Harding, H.P., Zhang, Y., Zeng, H., Novoa, I., Lu, P.D., Calfon, M., Sadri, N., Yun, C., Popko, B., Paules, R., Stojdl, D.F., Bell, J.C., Hettmann, T., Leiden, J.M. Ron, D. (2003) An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Molecular cell, 11, 619 633.
19. He, C.H., Gong, P., Hu, B., Stewart, D., Choi, M.E., Choi, A.M.K. Alam, J. (2001) Identification of activating transcription factor 4 (ATF4) as an Nrf2-interacting Protein. Implication for heme oxygenase-1 gene regulation. Journal of Biological Chemistry, 276, 20858 20865.
20. Hershko, A. (1997) Roles of ubiquitin-mediated proteolysis in cell cycle control. Current Opinion in Cell Biology, 9, 788 799.
21. Holcik, M. Sonenberg, N. (2005) Translational control in stress and apoptosis. Nature Review Molecular Cell Biology, 6, 318 327.
22. Isham, C.R., Tibodeau, J.D., Jin, W., Xu, R., Timm, M.M. Bible, K.C. (2007) Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood, 109, 2579 2588.
23. Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., Yamamoto, M. Nabeshima, Y. (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochemical and Biophysical Research Communications, 236, 313 322.
24. Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J.D. Yamamoto, M. (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes and Development, 13, 76 86.
25. Iwakoshi, N.N., Lee, A.H., Vallabhajosyula, P., Otipoby, K.L., Rajewsky, K. Glimcher, L.H. (2003) Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nature immunology, 4, 321 329.
26. Jang, H.H., Lee, K.O., Chi, Y.H., Jung, B.G., Park, S.K., Park, J.H., Lee, J.R., Lee, S.S., Moon, J.C. Yun, J.W. (2004) Two Enzymes in One: two yeast peroxiredoxins display oxidative stress-dependent switching from a peroxidase to a molecular chaperone function. Cell, 117, 625.
27. Jiang, H.Y. Wek, R.C. (2005) Phosphorylation of the alpha-subunit of the eukaryotic initiation factor-2 (eIF2alpha) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition. Journal of Biological Chemistry, 280, 14189 14202.
28. Jourdan, M., Ferlin, M., Legouffe, E., Horvathova, M., Liautard, J., Rossi, J.F., Wijdenes, J., Brochier, J. Klein, B. (1998) The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. British Journal Haematology, 100, 637 646.
29. Lee, A.H., Iwakoshi, N.N., Anderson, K.C. Glimcher, L.H. (2003) Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 9946 9951.
30. van Leyen, K., Siddiq, A., Ratan, R.R. Lo, E.H. (2005) Proteasome inhibition protects HT22 neuronal cells from oxidative glutamate toxicity. Journal of Neurochemistry, 92, 824 830.
31. Ling, Y.H., Liebes, L., Zou, Y. Perez-Soler, R. (2003) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. Journal of Biological Chemistry, 278, 33714 33723.
32. Meiners, S., Ludwig, A., Lorenz, M., Dreger, H., Baumann, G., Stangl, V. Stangl, K. (2006) Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radical Biology and Medicine, 40, 2232.
33. Minami, T., Adachi, M., Kawamura, R., Zhang, Y., Shinomura, Y. Imai, K. (2005) Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity. Clinical Cancer Research, 11, 5248 5256.
34. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Treon, S.P., Munshi, N.C., Richardson, P.G., Hideshima, T. Anderson, K.C. (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proceedings of the National Academy of Sciences of the United States of America, 99, 14374 14379.
35. Obeng, E.A., Carlson, L.M., Gutman, D.M., Harrington, Jr., W.J., Lee, K.P. Boise, L.H. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood, 107, 4907 4916.
36. Pei, X.Y., Dai, Y. Grant, S. (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clinical Cancer Research, 10, 3839 3852.
37. Reimold, A.M., Iwakoshi, N.N., Manis, J., Vallabhajosyula, P., Szomolanyi-Tsuda, E., Gravallese, E.M., Friend, D., Grusby, M.J., Alt, F. Glimcher, L.H. (2001) Plasma cell differentiation requires the transcription factor XBP-1. Nature, 412, 300 307.
38. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487 2498.
39. Sanderson, R.D. Borset, M. (2002) Syndecan-1 in B lymphoid malignancies. Annals of Hematology, 81, 125 135.
40. Sekhar, K.R., Yan, X.X. Freeman, M.L. (2002) Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2. Oncogene, 21, 6829 6834.
41. Shaffer, A.L., Shapiro-Shelef, M., Iwakoshi, N.N., Lee, A.H., Qian, S.B., Zhao, H., Yu, X., Yang, L., Tan, B.K., Rosenwald, A., Hurt, E.M., Petroulakis, E., Sonenberg, N., Yewdell, J.W., Calame, K., Glimcher, L.H. Staudt, L.M. (2004) XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity, 21, 81 93.
42. Tan, S., Somia, N., Maher, P. Schubert, D. (2001) Regulation of antioxidant metabolism by translation initiation factor 2alpha. Journal of Cell Biology, 152, 997 1006.
43. Tietze, F. (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Analytical Biochemistry, 27, 502 522.
44. Usami, H., Kusano, Y., Kumagai, T., Osada, S., Itoh, K., Kobayashi, A., Yamamoto, M. Uchida, K. (2005) Selective induction of the tumor marker glutathione S-transferase P1 by proteasome inhibitors. Journal of Biological Chemistry, 280, 25267 25276.
45. Yang, Y., Macleod, V., Dai, Y., Khotskaya-Sample, Y., Shriver, Z., Venkataraman, G., Sasisekharan, R., Naggi, A., Torri, G., Casu, B., Vlodavsky, I., Suva, L.J., Epstein, J., Yaccoby, S., Shaughnessy, Jr., J.D., Barlogie, B. Sanderson, R.D. (2007) The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood, 110, 2041 2048.
46. Zou, W., Yue, P., Lin, N., He, M., Zhou, Z., Lonial, S., Khuri, F.R., Wang, B. Sun, S.-Y. (2006) Vitamin C Inactivates the Proteasome Inhibitor PS-341 in Human Cancer Cells. Clinical Cancer Research, 12, 273 280.